AGP Executive Report
Last update: 3 hours agoClinical Trials Acceleration: The FDA opened applications for its Expedited IND Pilot (Operation TrialBlazer), aiming to speed first-in-human timelines via sponsor–qualified research institution pairs and iterative IND component review. AI in Drug Development: A Tufts CSDD benchmarking study found sourcing model choice doesn’t consistently drive trial performance; operating model design and partner coordination do. Patient-Centered Execution: uMotif CEO Andrea Valente argues AI can’t replace the patient-site relationship—trial success depends on mapping the full patient journey and educating both sides together. Rare Disease Evidence Engineering: New guidance highlights building submission-grade real-world evidence from the start when registries don’t exist, with cohort and endpoint decisions treated as design inputs. Pharma Approvals: FDA cleared Lilly’s Olumiant for pediatric severe alopecia areata, expanding treatment options for adolescents. AI Infrastructure & Power: Analysts note AI data centers are pushing demand for on-site generation and new financing structures as grid connections lag. Applied AI in Industry: Universal Music Group named Òscar Celma SVP for Applied AI and Machine Learning, bringing Spotify-style AI features into global operations.
Note: AI summary from news headlines; neutral sources weighted more to help reduce bias in the result. Feedback is welcome. Please let us know if you have any comments or suggestions about the AGP Executive Report.